Table 3 Events during the follow-up
Classification of all events | Periportal HCC (N = 56) | Nonperiportal HCC (N = 177) | P value |
|---|---|---|---|
Tumor Events after RFA | |||
 LTP | *15 (28.8%) | 24 (13.6%) | 0.0099 |
 IDR | *23 (44.2%) | 40 (22.6%) | 0.0012 |
 Extrahepatic recurrence | *12 (23.1%) | 14 (7.9%) | 0.0010 |
 PVTT | 16 (28.6%) | 12 (6.8%) | <0.0001 |
2nd-line treatments | |||
 TACE | 1 | 3 | – |
 RFA | 6 | 11 | – |
 TACE+RFA | 11 | 18 | – |
 Surgical resection | 3 | 4 | – |
 Liver transplantation | 1 | 1 | – |
 Radiation therapy | 1 | 0 | – |
 Systemic therapy | 1 | 0 | – |
 Systemic therapy+TIPS | 1 | 0 | – |
 Systemic therapy+TACE±RFA | 5 | 9 | – |
 Support therapy | 3 | 5 | – |
 Unknown | 2 | 0 | – |
Major complication | 0.1346 | ||
 Total | 6 (10.7%) | 9 (5.1%) | |
 Hepatic infraction | 2 | 0 | |
 Portal vein thrombosis | 4 | 5 | |
 Biloma | 0 | 1 |  |
 Liver abscess | 0 | 1 |  |
 Bleeding | 0 | 2 | |